Skip to main content

A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes

Completed · Phase 2 · NCT06603571

Conditions: Obesity, Overweight

At a glance

Research payments reported, 2025
$8.2M
U.S. investigators named
52
Sites paid
52
Planned or actual enrollment
367

About the trial

Sponsor
Eli Lilly and Company
Tested
LY3841136 (drug), Tirzepatide (drug), Placebo (drug)
Dates
Started 2024-09-20; completion 2026-09-14
Results posted
Not yet

The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to investigate the safety and efficacy of LY3841136 for chronic weight management alone or in combination with Tirzepatide across a wide dose range in participants with Type 2 Diabetes. Participation in the study will last about 64 weeks.

From ClinicalTrials.gov, last updated 2026-09-29. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Eli Lilly and Company reported $8.2M in research payments for this study in 2025 (102 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • Indago Research & Health Center Inc $1.2M
  • Texas Valley Clinical Research LLC $630,943
  • New Horizon Research Center $579,046
  • Charter Research LLC $568,008
  • Las Vegas Medical Research LLC $340,946
  • Great Lakes Clinical Trials $337,716
  • Danville Orthopedic Clinic Inc $336,599
  • Velocity Clinical Research Inc $327,593
  • Endocrine Ips PLLC $297,002
  • Headlands Horizons LLC $242,254
  • Sociedad Espanola De Medicina De La Adolescencia $233,434
  • Tribe Clinical Research LLC $232,160
  • Erg Holding Co LLC DBA St Louis Clinical Trials LLC $229,038
  • Lucas Research Inc $222,857
  • Central Washington Health Services $213,937
  • Ascension Medical Group $207,570
  • Peninsula Headlands LLC $202,796
  • Institute for Liver Health LLC $170,583
  • Ima Evaluations LLC DBA Ima Clinical Research $159,338
  • Lucida Clinical Trials $151,675
  • Cotton Oneil Msd of Stormont Vail Healthcare $144,696
  • Studymetrix Research LLC $130,403
  • Suncoast Clinical Research $125,421
  • Monroe Biomedical Research $102,865
  • Cti Holdings Inc DBA Community Research Management Associates Inc $93,622
  • Iowa Diabetes and Endocrinology Rsrch Cntr $92,125
  • Clinvest Headlands LLC $84,977
  • Stamford Therapeutics Consortium $84,949
  • Rochester Clinical Research Inc $78,032
  • Norcal Medical Research Inc $74,823
  • Northshore University Healthsystem - Evanston Hospital, IL $64,480
  • Tekton Research Inc $42,671
  • Hope Research Institute LLC $41,879
  • Future Search Trials of Dallas LP $28,880
  • Diabetes and Endocrinology Consultants $16,638
  • Endeavor Clinical Trials PA $15,645
  • Medical Research PArtners $13,274
  • Medex Healthcare Research Inc $13,143
  • Northeast Research Institute $10,210
  • Wenatchee Valley Hospital $9,846
  • Palos Verdes Medical Group $9,080
  • Clinvest Research LLC $8,835
  • Dent Neurosciences Research Center Inc $7,750
  • Lightship Inc $6,717
  • Yshay Shlesinger MD $6,524
  • Arcturus Healthcare PLC, Troy Internal $6,148
  • University at Buffalo $5,975
  • Knownwell $5,975
  • Futuresearch Trials of Neurology LP $4,761
  • North Suffolk Neurology $4,702
  • Medication Management LLC $1,400
  • $218
  • Cleveland Clinic, OH $50

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.